Hereditary Spherocytosis

Spherocytes beside normal disc-shaped red cells
Spherocytes beside normal disc-shaped red cells

Table of Contents

  1. What Hereditary Spherocytosis Is
  2. Genetics and Inheritance Patterns
  3. Pathophysiology: Membrane Defects and Spherocyte Formation
  4. Clinical Presentation: The Classic Triad
  5. Aplastic Crisis and Parvovirus B19
  6. Diagnosis: Smear, Eosin-5-Maleimide Binding, and Coombs Test
  7. Laboratory Findings and Distinguishing Features
  8. Treatment: Folate, Splenectomy, and Vaccination
  9. Splenectomy: Indications, Risks, and Timing
  10. Long-Term Outcomes and Monitoring
  11. Key Research Papers
  12. Connections
  13. Featured Videos

What Hereditary Spherocytosis Is

Hereditary spherocytosis (HS) is the most common inherited red blood cell (RBC) membrane disorder in individuals of Northern European ancestry, affecting approximately 1 in 2,000 people in that population. It is characterized by a defect in the proteins that anchor the red blood cell's outer lipid bilayer to its internal cytoskeletal network, causing the cells to lose their normal biconcave disc shape and adopt a spherical form — the defining spherocyte. These misshapen, rigid spherocytes cannot deform adequately to squeeze through the narrow sinusoids of the spleen, where they are trapped and destroyed, leading to hemolytic anemia, jaundice, and splenomegaly.

Unlike many hereditary anemias that are concentrated in malaria-endemic regions, hereditary spherocytosis is reported worldwide and is the most common inherited anemia in people of northern European ancestry. That pattern is sometimes explained as a founder effect rather than a malaria-protective advantage; a 2008 Lancet review reports many isolated mutations and no common hereditary spherocytosis mutations (PMID 18940465). The disorder spans a wide clinical spectrum — from a mild, well-compensated anemia that may not be diagnosed until adulthood, to a severe hemolytic anemia requiring early transfusion support in infancy. Most patients fall in the mild-to-moderate range and can lead normal lives with monitoring and, when needed, surgical intervention.

Back to Table of Contents

Genetics and Inheritance Patterns

Hereditary spherocytosis arises from mutations in genes encoding key red cell membrane-cytoskeleton anchor proteins. Understanding which protein is affected helps predict disease severity and guides genetic counseling.

Autosomal Dominant Inheritance (About 75% of Cases)

The majority of hereditary spherocytosis cases follow an autosomal dominant inheritance pattern, meaning a single mutant allele from one parent is sufficient to cause disease. The affected genes include:

Autosomal Recessive Inheritance (Part of the Remaining 25%)

The remaining approximately 25% of HS cases are either autosomal recessive or new (de novo) mutations taken together (PMID 41721551). A recessive pattern requires two mutant alleles (homozygous or compound heterozygous); a 1990 German family study showed it in 20% of families (PMID 2391596). Autosomal recessive HS tends to be more clinically severe, as both alleles of the affected gene are non-functional:

De Novo Mutations

New (de novo) mutations occur in patients with no family history of the disorder and share that remaining 25% with the recessive cases, so the percentages do not add on top of each other. The share varies by study and by who is tested: in a 2026 hospital series of 59 Chinese children, 37 (62.7%) had de novo mutations (PMID 41721551). This group is particularly relevant when evaluating an infant or child with unexplained hemolytic anemia and negative family history — hereditary spherocytosis remains possible even without an affected parent.

Back to Table of Contents

Pathophysiology: Membrane Defects and Spherocyte Formation

The red blood cell's ability to survive its 120-day lifespan while repeatedly deforming to pass through capillaries narrower than the cell itself depends on the structural integrity of its membrane skeleton. In hereditary spherocytosis, defects in this skeleton disrupt the vertical connections between the lipid bilayer and the underlying cytoskeleton, leading to progressive membrane loss and spherocyte formation.

The Normal Red Cell Membrane Architecture

The red cell membrane is a bilayer lipid membrane supported by a two-dimensional cytoskeletal network on its inner surface. The cytoskeleton is composed primarily of spectrin heterodimers (alpha-spectrin + beta-spectrin) that associate into tetramers, cross-linked by short actin filaments and protein 4.1 into a hexagonal lattice. This lattice is tethered to the lipid bilayer through two types of vertical connections:

The result is a membrane that is simultaneously strong (cytoskeleton resists deformation) and flexible (lipid bilayer can deform). This combination allows normal biconcave RBCs to squeeze through capillaries as narrow as 3 micrometers.

Membrane Vesiculation: How Spherocytes Form

In hereditary spherocytosis, mutations in ankyrin, spectrin, band 3, or protein 4.2 weaken the vertical connections between cytoskeleton and lipid bilayer. This weakness causes the outer lipid bilayer to spontaneously vesiculate — small lipid blebs pinch off from unsupported areas of the membrane and are released into the circulation. With each pass through the circulation, the cell loses surface area through membrane vesiculation while its internal volume remains relatively constant. The result is a progressive increase in the surface area-to-volume ratio imbalance: the cell becomes more spherical as it loses membrane, ultimately forming the classic spherocyte — a round, dense, small cell with no central pallor.

Splenic Trapping and Destruction

The spleen is the primary site of spherocyte destruction. Normal red cells easily pass through the narrow interendothelial slits of the splenic sinusoids (2–3 µm diameter, smaller than the 8 µm diameter of a normal RBC), deforming their flexible biconcave disc shape to squeeze through. Spherocytes, having lost surface area relative to volume and being more rigid, cannot deform adequately. They become entrapped in the splenic red pulp cords and sinusoids, where macrophages recognize and phagocytose them — this is extravascular hemolysis. The spleen also worsens spherocyte formation by exposing trapped cells to acidic, glucose-deprived, oxidatively stressed conditions that accelerate membrane vesiculation. Splenectomy, therefore, removes the primary destruction site and dramatically improves anemia even though spherocytes remain present on the blood smear after surgery.

Back to Table of Contents

Clinical Presentation: The Classic Triad

The classic clinical triad of hereditary spherocytosis — anemia, jaundice, and splenomegaly — reflects the consequences of chronic extravascular hemolysis. The severity of each component correlates with the degree of hemolysis, which in turn reflects the severity of the underlying membrane defect.

Anemia

Anemia in HS ranges from fully compensated (hemoglobin within normal range due to adequate erythropoietic compensation) to moderately severe (hemoglobin 8–11 g/dL), with rare severe cases requiring transfusion. Most patients with mild-to-moderate HS have chronic, stable anemia with reticulocytosis reflecting the bone marrow's compensatory increased red cell production. Fatigue, pallor, reduced exercise tolerance, and exertional dyspnea are the dominant symptoms. Many patients with mild HS are not diagnosed until adulthood, when routine blood work reveals unexplained mild anemia with an elevated MCHC (mean corpuscular hemoglobin concentration) — a laboratory finding that is virtually unique to HS among the hemolytic anemias.

Jaundice

Jaundice in HS is caused by the overproduction of unconjugated (indirect) bilirubin from hemoglobin released during red cell destruction. The liver conjugates bilirubin and excretes it into bile, but when hemolysis exceeds hepatic conjugating capacity, indirect bilirubin accumulates in the blood, causing scleral icterus and skin jaundice. In HS, jaundice is typically low-grade and chronic, often described as a faint yellow tinge of the sclerae rather than the deep yellow jaundice of hepatic or biliary disease. Parents of infants with HS often report persistent neonatal jaundice extending beyond the usual 2 weeks. Episodic worsening of jaundice — particularly during intercurrent viral illnesses — reflects transient increases in hemolysis.

Splenomegaly

Splenomegaly — an enlarged spleen palpable on abdominal examination — is present in the majority of patients with HS. The spleen enlarges because it is overworking: increased reticuloendothelial activity from constant trapping and phagocytosis of spherocytes drives splenic hyperplasia. In severe HS, the spleen can become massive, causing left upper quadrant discomfort, early satiety, and occasionally hypersplenism (exacerbating the anemia through sequestration). The enlarged spleen is also at risk for traumatic rupture in contact sports or accidents, a consideration in management decisions about activity restriction and splenectomy timing.

Pigment Gallstones

A major long-term complication of chronic hemolysis in HS is the formation of pigment gallstones (bilirubin gallstones). Excess bilirubin secreted into bile precipitates as calcium bilirubinate, forming black pigment stones in the gallbladder. The cumulative incidence of gallstones in HS is substantial: approximately 20–30% of adolescents and 50% or more of adults with untreated moderate-to-severe HS develop cholelithiasis. Gallstones can cause biliary colic, cholecystitis, choledocholithiasis, and cholangitis. When symptomatic cholelithiasis develops in a patient already requiring splenectomy for HS, laparoscopic cholecystectomy is typically performed simultaneously, avoiding a second operation.

Back to Table of Contents

Aplastic Crisis and Parvovirus B19

Among the most dangerous acute complications of hereditary spherocytosis is the aplastic crisis — a temporary but profound suppression of red blood cell production triggered by parvovirus B19 infection. Understanding this complication is critical because it is potentially life-threatening and requires immediate recognition and management.

Parvovirus B19: Mechanism of Red Cell Aplasia

Parvovirus B19 is a small, non-enveloped DNA virus that has a specific tropism for human erythroid progenitor cells in the bone marrow. The virus binds to the P blood group antigen (globoside) expressed on the surface of erythroid progenitors and early erythroblasts, enters the cell, and replicates, causing apoptosis and destruction of the progenitor population. In immunologically normal individuals without chronic hemolysis, transient red cell aplasia lasting 7–10 days is clinically silent because normal red cells survive for 120 days — the brief production pause barely affects the peripheral red cell count.

In patients with hereditary spherocytosis, the situation is dramatically different. Because spherocytes are continuously destroyed at an accelerated rate, the HS patient's red cell survival is only 10–20 days (versus the normal 120 days). The bone marrow must produce red cells at 5–10 times the normal rate to maintain hemoglobin levels. When parvovirus B19 abruptly shuts down this high-rate erythropoiesis, red cell counts fall precipitously within days to a week. The hemoglobin can drop to 2–4 g/dL, levels causing hemodynamic compromise, congestive heart failure, and cardiovascular collapse.

Clinical Recognition of Aplastic Crisis

The aplastic crisis presents as an acute, severe worsening of anemia in a patient with known HS (or sometimes as the first presentation of previously undiagnosed HS). Characteristic features that distinguish aplastic crisis from a simple hemolytic exacerbation:

Treatment and Family Considerations

Aplastic crisis is managed with red blood cell transfusion to maintain adequate hemoglobin while the bone marrow recovers. Recovery of erythropoiesis typically occurs within 1–2 weeks as the immune system clears parvovirus B19 infection, producing immunoglobulin M then immunoglobulin G (IgG) anti-parvovirus antibodies. Immunity after infection is lifelong in immunocompetent individuals. Because parvovirus B19 is highly contagious, an aplastic crisis in one family member with HS is a reason siblings and parents with HS are evaluated, as they may simultaneously develop aplastic crises. Parvovirus B19 can cause hydrops fetalis in the fetus of a pregnant woman without prior immunity, so exposure in the household is a hazard for her. No antiviral therapy is available for acute parvovirus B19 infection in immunocompetent hosts; intravenous immunoglobulin can be used in chronic infection in immunocompromised patients.

Back to Table of Contents

Diagnosis: Smear, Eosin-5-Maleimide Binding, and Coombs Test

The diagnosis of hereditary spherocytosis rests on the combination of clinical features (family history, hemolytic anemia, jaundice, splenomegaly), peripheral blood smear findings, and confirmatory laboratory tests. The diagnostic approach has evolved significantly over the past two decades, with the eosin-5-maleimide (EMA) binding test replacing the older osmotic fragility test as the preferred confirmatory test.

Peripheral Blood Smear: The Spherocyte

The peripheral blood smear is the first and most important diagnostic test. In HS, the smear shows spherocytes — small, round, densely stained red cells that lack the central pallor of normal biconcave red cells. A normal red blood cell has a central area of pallor (lighter staining) occupying approximately one-third of the cell's diameter, reflecting the biconcave disc's thinner central region. Spherocytes have lost this central pallor entirely; they appear as uniformly dense, deeply stained, round cells that are typically smaller than normal red cells (microspherocytes).

The percentage of spherocytes on the smear roughly correlates with disease severity. It is important to note that spherocytes are not pathognomonic for HS — they also appear in autoimmune hemolytic anemia (AIHA), ABO incompatibility (in neonates), severe thermal burns, and occasionally other conditions. The clinical context and additional testing distinguish these entities. Importantly, the direct antiglobulin test (Coombs test) is negative in HS, differentiating it from AIHA where antibody-mediated destruction is the mechanism.

Eosin-5-Maleimide Binding Test

The eosin-5-maleimide binding test is now considered the first-line confirmatory test for hereditary spherocytosis. Eosin-5-maleimide is a fluorescent dye that covalently binds to lysine residues on band 3 protein (and also to band 4.2 and Rh-related proteins) on the red cell surface. The amount of eosin-5-maleimide fluorescence measured by flow cytometry directly reflects the quantity of band 3 protein present per red cell.

In HS, because band 3 protein is either directly mutated (band 3 deficiency) or secondarily reduced through loss of membrane surface (band 3 leaves the membrane as the bilayer vesiculates), eosin-5-maleimide fluorescence is reduced — typically 15–30% below the normal range. The eosin-5-maleimide binding test has both high sensitivity (92.7% in a 2000 study, 93% in a 2012 study) and high specificity (99.1% and 98%) for HS, and it has largely replaced the osmotic fragility test (PMID 11122157; PMID 22058213). A negative result (normal or elevated eosin-5-maleimide fluorescence) makes hereditary spherocytosis less likely but does not exclude it, because no single test catches every case. Reduced readings are not unique to HS either: the 2000 study also found them in congenital dyserythropoietic anemia type II, South-east Asian ovalocytosis and cryohydrocytosis.

A 2012 Italian study compared the tests in 150 patients. Sensitivity was 93% for the dye test, 95% for the acidified glycerol lysis test, 91% for the Pink test, and 68% (fresh blood) or 81% (incubated blood) for the sodium chloride osmotic fragility test, falling to 53% and 64% in compensated cases. The authors state that each type of test fails to diagnose some cases; the dye test and the acidified glycerol lysis test together identified every patient in the series (PMID 22058213).

Direct Antiglobulin Test (DAT / Coombs Test)

The direct antiglobulin test is a crucial part of the diagnostic workup for hereditary spherocytosis, not to diagnose HS directly, but to exclude autoimmune hemolytic anemia (AIHA) as the cause of spherocytosis and hemolysis. In AIHA, the DAT is positive — immunoglobulin G antibodies (warm AIHA) or complement C3d (cold AIHA) are detected on the red cell surface. In HS, the DAT is negative. This distinction is critical because the treatments are completely different: AIHA is treated with immunosuppression (corticosteroids, rituximab), while HS is managed with folate supplementation, splenectomy, and vaccination. A positive DAT in a patient with apparent spherocytosis points the diagnosis toward AIHA.

Historical Tests Now Largely Replaced

The osmotic fragility test — measuring the osmolarity at which red cells lyse — was historically the standard confirmatory test for HS. Spherocytes, having less membrane reserve, lyse at higher osmolarity (higher NaCl concentration) than normal red cells. While the osmotic fragility test can confirm HS, it is less sensitive than eosin-5-maleimide binding (approximately 68% sensitivity on fresh blood, 81% on incubated blood), can be normal in mild HS, and requires special handling. It has been largely superseded by eosin-5-maleimide binding in centers with flow cytometry capacity. The cryohemolysis test — measuring hemolysis after brief heating to 37°C then cooling — is another alternative with good sensitivity but similar limitations. Genetic testing can definitively confirm the diagnosis and identify the specific mutation, but is typically reserved for cases with atypical presentations or when family genetic counseling is specifically requested.

Back to Table of Contents

Laboratory Findings and Distinguishing Features

Several laboratory findings in hereditary spherocytosis are characteristic enough to guide diagnosis even before confirmatory testing is performed.

Elevated MCHC: The Most Specific Screening Marker

The mean corpuscular hemoglobin concentration (MCHC) — a measure of the hemoglobin concentration per unit volume of red cells — is elevated in HS, typically above 36 g/dL (normal: 32–36 g/dL). This elevation reflects the abnormally dense, dehydrated nature of spherocytes: the cells have lost surface area (membrane) but retained their hemoglobin content, so the hemoglobin concentration per cell volume is increased. An elevated MCHC is not specific for HS alone, but among all hemolytic anemias, HS consistently produces the highest MCHC values. An MCHC above 36 g/dL in a patient with hemolytic anemia raises the question of HS and is a common reason for eosin-5-maleimide binding testing.

Elevated RDW and Reticulocytosis

The red cell distribution width (RDW) is elevated in HS, reflecting the coexistence of small, dense microspherocytes and large reticulocytes (young red cells released by the hyperactive bone marrow). The reticulocyte count is elevated (reticulocytosis) — typically 5–20% in moderate HS — as the bone marrow compensates for accelerated destruction. During aplastic crisis, the reticulocyte count drops precipitously to near zero, a key diagnostic clue.

Hemolysis Markers

The standard markers of hemolysis are present in HS:

Neonatal Presentation

Hereditary spherocytosis often presents in the neonatal period with prolonged indirect hyperbilirubinemia (neonatal jaundice) requiring phototherapy or, rarely, exchange transfusion. The combination of neonatal jaundice with a positive family history of anemia, jaundice, gallstones, or splenectomy is a common reason for a smear and an eosin-5-maleimide binding test. ABO incompatibility (which can also cause neonatal spherocytosis and jaundice) is distinguished from HS by the positive DAT in ABO incompatibility and the maternal blood type.

In a French study that followed 34 infants with HS through the first year of life, hemoglobin was usually normal at birth and then fell sharply over the next 20 days, and 26 of the 34 needed a blood transfusion. The authors link careful monitoring in the first 6 months of life to appropriate care (PMID 10627440).

Back to Table of Contents

Treatment: Folate, Splenectomy, and Vaccination

The management of hereditary spherocytosis is tailored to disease severity. Most patients with mild HS require only folate supplementation and periodic monitoring. Those with moderate-to-severe HS may benefit from splenectomy, with careful attention to timing and infectious prophylaxis. Surgery is now used in a minority: in a large series over 1980–2005, splenectomy was performed in only 20% of patients, and the rate has declined in the last decade. The 2017 European recommendations on splenectomy rest on expert opinion, because the authors found no randomized, case-control or cohort studies on the question (PMID 28550188).

Folic Acid Supplementation

Folic acid (vitamin B9) supplementation is described for all patients with moderate-to-severe HS and considered for mild HS. The rationale is straightforward: chronic hemolysis dramatically increases the rate of red cell production, which proportionally increases the demand for folate (required for DNA synthesis in erythroid progenitors). When folate demand chronically exceeds dietary intake, megaloblastic anemia superimposes on the underlying hemolytic anemia — a preventable complication called megaloblastic crisis. Standard dosing is folic acid 1–5 mg/day orally. This is particularly important in pregnant women with HS, who have increased folate requirements both from hemolysis and from fetal development.

Blood Transfusion in Acute Settings

Red blood cell transfusion is the primary treatment for acute, severe anemia in HS — most commonly during aplastic crises triggered by parvovirus B19, and occasionally during severe hemolytic exacerbations in the setting of intercurrent infections. Transfusion thresholds in HS follow general principles: transfuse for hemoglobin below 7–8 g/dL in symptomatic patients, or higher thresholds in patients with cardiorespiratory compromise. Patients with severe HS may require chronic transfusion support before splenectomy is performed at an appropriate age. Leukoreduced, irradiated, and if needed phenotype-matched blood products are used to minimize alloimmunization risk in transfusion-dependent patients.

Management of Gallstones

Surveillance with abdominal ultrasound is used to monitor for gallstone formation, particularly in adolescents and adults with moderate-to-severe HS who have not undergone splenectomy (which reduces bilirubin overproduction and thereby decreases gallstone risk). When symptomatic cholelithiasis develops (biliary colic, cholecystitis), laparoscopic cholecystectomy is indicated. In patients also meeting criteria for splenectomy, both procedures are ideally performed simultaneously to avoid two separate operations and their associated anesthetic and infectious risks.

Back to Table of Contents

Splenectomy: Indications, Risks, and Timing

Splenectomy — surgical removal of the spleen — is the most effective treatment for hereditary spherocytosis. By removing the organ responsible for trapping and destroying spherocytes, splenectomy eliminates the primary site of hemolysis and dramatically improves anemia in nearly all patients. However, splenectomy carries lifelong infectious risks that require careful consideration, particularly in children.

How Splenectomy Works (and Its Limits)

After splenectomy, spherocytes continue to form and circulate — the underlying membrane defect persists, and spherocytes remain visible on the peripheral blood smear for the patient's lifetime. What changes is that spherocytes are no longer trapped in splenic sinusoids and destroyed. The freed spherocytes, despite being less deformable than normal red cells, can survive in the circulation for a substantially longer time. Hemolysis decreases, reticulocyte count falls, and hemoglobin rises, typically to near-normal or normal levels. Most patients with moderate HS achieve complete or near-complete normalization of hemoglobin after splenectomy; in severe disease the response is partial, and a 1990 study reports that a considerable degree of increased hemolysis persists (PMID 2391596). Bilirubin levels fall as well, reducing the risk of further pigment gallstone formation.

Indications for Splenectomy

Published guidance describes splenectomy for:

The 2017 European recommendations state that, in general, splenectomy is not indicated in patients with mild HS (PMID 28550188). The reasoning given is that the lifelong infectious risks of splenectomy outweigh the benefit when anemia is mild. Most people with mild HS are followed with observation and folate supplementation.

Infection is not the only long-term risk. In a study of families with this condition, by age 70 artery events had occurred in 22% of women and 32% of men who had the operation, against 3% and 2% of affected people who kept the spleen (hazard ratio 7.2); vein clots had occurred in 20% and 19% against 6% and 4% (hazard ratio 3.3) (PMID 18485083). The 2017 recommendations note that only a few such events have been reported individually, and that another study of 39 adults with HS found no thrombotic events over a median of 25 years (PMID 28550188).

Timing: Why to Wait in Children

The spleen plays a critical role in the immune response, particularly against encapsulated bacteria — organisms with polysaccharide capsules that evade phagocytosis and require opsonization via antibodies or complement to be cleared. The key pathogens are Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. After splenectomy, patients are at lifelong increased risk of rapidly fatal overwhelming post-splenectomy infection (OPSI) — a sepsis syndrome that can progress from initial fever to cardiovascular collapse and death within 12–24 hours from these encapsulated organisms.

In children, the spleen's immunologic role is particularly important. Splenectomy in children under 5 years of age carries a substantially higher risk of OPSI (an estimated 1–2% annual risk in young children, a figure with no published source traced for it) compared to adults. The 2017 European recommendations state that the current risk above age 5 is difficult to estimate, because most studies are retrospective and include people with different diseases who were not fully immunized (PMID 28550188). Current guidelines therefore recommend deferring splenectomy until age 5–6 years at the earliest in most patients, and until age 12+ in mild-to-moderate cases where the delay is medically acceptable. This delay allows sufficient maturation of the humoral immune system so that asplenic patients can mount better antibody responses.

Laparoscopic splenectomy (minimally invasive) is now the standard surgical approach, offering shorter hospitalization and recovery compared to open splenectomy. Partial splenectomy — removing only part of the spleen to reduce hemolysis while preserving some splenic immune function — is an option in young children who require early intervention, though residual splenic tissue can hypertrophy and hemolysis may recur over time. Usually 80–90% of the enlarged spleen is removed. In follow-up of 39 severely affected children under 5 at surgery, 50% later needed a total splenectomy, a median of 5 years afterwards (PMID 28550188).

Pre-Splenectomy Vaccination

Guidance describes vaccination against the encapsulated bacteria responsible for OPSI before splenectomy, given at least 2 weeks before surgery to allow an adequate immune response before the spleen is removed:

Post-splenectomy, vaccination schedules require periodic boosting, particularly for pneumococcal and meningococcal vaccines. Children undergoing splenectomy before age 5 typically receive penicillin prophylaxis (oral amoxicillin or penicillin V) daily until at least age 18 to reduce OPSI risk during the years of greatest susceptibility. Adults may be given an emergency antibiotic supply (amoxicillin or amoxicillin-clavulanate) to take at the first sign of fever, with fever in this setting treated by hospitals as urgent.

Back to Table of Contents

Long-Term Outcomes and Monitoring

With appropriate management, patients with hereditary spherocytosis lead normal lifespans. The goals of long-term management are preventing complications (aplastic crisis, gallstones, megaloblastic anemia), monitoring for disease progression, and ensuring lifelong infectious prophylaxis in asplenic patients.

Mild HS: Observation and Monitoring

Most patients with mild HS managed without splenectomy require periodic monitoring of hemoglobin, reticulocyte count, bilirubin, and abdominal ultrasound for gallstone surveillance. The primary concern is the development of symptomatic gallstones and, less commonly, aplastic or megaloblastic crises. Folic acid supplementation continues lifelong. Activity restriction is generally not required, though contact sports carry a risk of traumatic splenic rupture in the setting of significant splenomegaly.

Iron overload without transfusions is also described in adults with this condition, though it is poorly documented. A study of 13 such adults found no link with the spherocytosis genes or with the main hemochromatosis variant (HFE p.Cys282Tyr); some carried variants in other iron-related genes, and the authors call for larger studies (PMID 39632350).

After Splenectomy: Lifelong Infection Vigilance

The most important long-term management task after splenectomy is infectious risk management. Measures described for people without a spleen:

The list of dangerous germs is longer than the three encapsulated bacteria named above. The 2017 European recommendations add Plasmodium (malaria), Capnocytophaga after an animal bite, Babesia after a tick bite, and Bordetella holmesii. Risk is highest before age 5 and in the first year after surgery, and probably stays raised for life (PMID 28550188).

Genetic Counseling

Genetic counseling is available to families with hereditary spherocytosis and is used particularly in planning pregnancies. For autosomal dominant HS, each child of an affected parent has a 50% chance of inheriting the mutation. Prenatal testing is possible for families where the specific mutation has been identified. Neonatal screening of at-risk infants (positive family history) with peripheral blood smear and eosin-5-maleimide binding testing shortly after birth allows early detection and preparation for managing neonatal jaundice and aplastic crisis risk. Siblings of affected children are often evaluated for subclinical HS even if they appear clinically normal.

Back to Table of Contents

Key Research Papers

  1. Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol. 2004;41(2):142–164. — PubMed PMID: 15071791
  2. Eber SW, Armbrust R, Schröter W. Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis. J Pediatr. 1990;117(3):409–416. — PubMed PMID: 2391596
  3. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis — 2011 update. Br J Haematol. 2012;156(1):37–49. — PubMed PMID: 22055020
  4. King MJ, Zanella A. Hereditary red cell membrane disorders and laboratory diagnostic testing. Int J Lab Hematol. 2013;35(3):237–243. — PubMed PMID: 23480868
  5. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008;372(9647):1411–1426. — PubMed PMID: 18940465
  6. Da Costa L, Galimand J, Fenneteau O, Mohandas N. Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev. 2013;27(4):167–178. — PubMed PMID: 23664421
  7. Delhommeau F, Cynober T, Schischmanoff PO, et al. Natural history of hereditary spherocytosis during the first year of life. Blood. 2000;95(2):393–397. — PubMed PMID: 10627440
  8. Schilling RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis — a personal view. Br J Haematol. 2009;145(6):728–732. — PubMed PMID: 19388926
  9. Rescorla FJ, Engum SA, West KW, et al. Laparoscopic splenectomy has become the gold standard in children. Am Surg. 2002;68(3):297–301. — PubMed PMID: 11894857
  10. Casale M, Perrotta S. Splenectomy for hereditary spherocytosis: complete, partial or not at all? Expert Rev Hematol. 2011;4(6):627–635. — PubMed PMID: 22077527
  11. Gallagher PG, Forget BG. Hematologically important mutations: spectrin and ankyrin variants in hereditary spherocytosis. Blood Cells Mol Dis. 1998;24(4):539–543. — PubMed PMID: 9887280
  12. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152(2):257–265. — PubMed PMID: 2993431
  13. King MJ, Behrens J, Rogers C, Flynn C, Greenwood D, Chambers K. Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol. 2000;111(3):924–933. — PubMed PMID: 11122157
  14. Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica. 2012;97(4):516–523. — PubMed PMID: 22058213
  15. Iolascon A, Andolfo I, Barcellini W, et al. Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica. 2017;102(8):1304–1313. — PubMed PMID: 28550188
  16. Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost. 2008;6(8):1289–1295. — PubMed PMID: 18485083
  17. Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793–798. — PubMed PMID: 39264843
  18. Donaty L, Giansily-Blaizot M, Bertchansky I, et al. Iron overload in hereditary spherocytosis: Are genetic factors the cause? Br J Haematol. 2026;208(2):691–696. — PubMed PMID: 39632350
  19. Li Y, Wang Y, Liu T, et al. Clinical Characteristics and Gene Mutations of Hereditary Spherocytosis in 59 Chinese Children. Mol Genet Genomic Med. 2026;14(3):e70188. — PubMed PMID: 41721551

Search PubMed for more: Hereditary spherocytosis Hereditary spherocytosis splenectomy HS aplastic crisis

Back to Table of Contents

Connections

Back to Table of Contents